Literature DB >> 2155218

Development of specific functionally active receptors for platelet-activating factor in HL-60 cells following granulocytic differentiation.

D S Vallari1, R Austinhirst, F Snyder.   

Abstract

A human promyelocytic leukemia cell line (undifferentiated HL-60 cells) as well as a granulocyte form of HL-60 cells induced in vitro by exposure to dimethyl sulfoxide were examined for binding, metabolism, and biological responses to platelet-activating factor (PAF). Undifferentiated and differentiated HL-60 cells each exhibit a high capacity to incorporate and metabolize [3H]PAF at 37 degrees C; however, the amount of [3H]PAF that is assimilated by both cell populations is greatly reduced and its metabolism abolished at less than or equal to 4 degrees C. At 0 degrees C HL-60 granulocytes bind more [3H]PAF than their undifferentiated counterparts. Binding to differentiated cells reaches equilibrium within 80 min and is saturable, reversible and specific; PAF receptor antagonists WEB 2086, L-659,989, BN 52021, and kadsurenone abolish this specific [3H]PAF binding. In contrast, [3H]PAF uptake by undifferentiated HL-60 cells is neither saturable nor sensitive to specific receptor antagonists. Scatchard analyses reveal 5850 +/- 850 binding sites per differentiated HL-60 cell with a dissociation constant of 0.66 +/- 0.15 nM. In the presence of cytochalasin B, PAF (200 nM) induces degranulation only in differentiated cells and this response also is blocked by PAF receptor antagonists. Our results demonstrate that HL-60 cells develop specific and functionally active PAF receptors only after chemically induced differentiation into granulocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155218

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Solubilization of a functionally active platelet-activating factor receptor from rabbit platelets.

Authors:  J E Rogers; V Duronio; S I Wong; M McNeil; H Salari
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

Review 3.  Platelet-activating factor: receptors and signal transduction.

Authors:  W Chao; M S Olson
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

4.  Metabolism of platelet-activating factor in human haematopoietic cell lines. Differences between myeloid and lymphoid cells.

Authors:  M C Garcia; C Garcia; M A Gijon; S Fernandez-Gallardo; F Mollinedo; M Sanchez Crespo
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

5.  Regulation of platelet-activating-factor receptors and the desensitization response in polymorphonuclear neutrophils.

Authors:  J T O'Flaherty; D P Jacobson; J F Redman
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

6.  Regulation of phospholipase D and primary granule secretion by P2-purinergic- and chemotactic peptide-receptor agonists is induced during granulocytic differentiation of HL-60 cells.

Authors:  M S Xie; L S Jacobs; G R Dubyak
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

7.  Expression of human platelet-activating factor receptor gene in EoL-1 cells following butyrate-induced differentiation.

Authors:  T Izumi; S Kishimoto; T Takano; M Nakamura; Y Miyabe; M Nakata; C Sakanaka; T Shimizu
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

8.  In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.

Authors:  V G Brunton; P Workman
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.